- Conditions
- Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Interventions
- Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Julio Barredo, MD
- Other
- Eligibility
- 16 Years to 39 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 707
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Glioblastoma
- Interventions
- Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
- Drug · Radiation · Biological
- Lead sponsor
- Global Coalition for Adaptive Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Psoriasis
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Haemophilia A, Haemophilia A With Inhibitors
- Interventions
- NNC0365-3769 (Mim8) PPX
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 10 more
- Conditions
- Tobacco Dependence
- Interventions
- Usual care, Lung age, Contingency Management, Lung age + Contingency Management
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Multiple Sclerosis
- Interventions
- N-acetyl Cysteine
- Dietary Supplement
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
- Interventions
- Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring
- Drug · Device · Behavioral + 1 more
- Lead sponsor
- Clive Michelsen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Basalt, Colorado
- Conditions
- Head and Neck Neoplasms
- Interventions
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Drug
- Lead sponsor
- Ascendis Pharma A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 13 more
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
- Interventions
- Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
- Drug
- Lead sponsor
- Andrew E. Place, MD
- Other
- Eligibility
- 1 Year to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 5
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
- Conditions
- Breast Cancer
- Interventions
- MRI Abbreviated Scan, Abbreviated MRI Scan
- Diagnostic Test
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 40 Years to 74 Years · Female only
- Enrollment
- 166 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alexander Disease
- Interventions
- zilganersen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), Opioid Use Disorder
- Interventions
- Telehealth Behavioral Intervention for promoting HIV and HCV care and MOUD among Persons who inject drugs (PWID)
- Behavioral
- Lead sponsor
- University of Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Colbert, Georgia
- Conditions
- Cheek Augmentation, Correction of Age-related Midface Contour Deficiencies
- Interventions
- injection of RHA®4 in Midface, injection of Comparator Product in Midface
- Device
- Lead sponsor
- Teoxane SA
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chestnut Hill, Massachusetts
- Conditions
- Fracture Dislocation of Ankle Joint, Fracture Leg, Fracture Femur, Fracture Lower Leg, Fracture
- Interventions
- Bupivacaine, Exparel + Bupivacaine
- Drug
- Lead sponsor
- George Washington University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Alzheimer Disease, Down Syndrome
- Interventions
- ION269
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 35 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 5
- States / cities
- Indianapolis, Indiana • Kansas City, Kansas • Lexington, Kentucky + 2 more
- Conditions
- Opioid-use Disorder
- Interventions
- buprenorphine/naloxone oral product, injectable naltrexone, Pharmacy maintenance addiction care, oral naltrexone
- Drug · Other
- Lead sponsor
- Lifespan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Breast Cancer
- Interventions
- therapeutic autologous dendritic cells, aromatase inhibition therapy, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
- Biological · Drug · Genetic + 3 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Omaha, Nebraska
- Conditions
- Spinal Muscular Atrophy
- Interventions
- nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN, Head Neck Cancer, Head and Neck Squamous Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck, Squamous Cell Head and Neck Carcinoma, Oral Cavity, Oral Cavity Carcinoma
- Interventions
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Biological · Drug
- Lead sponsor
- VLP Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
- Interventions
- TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy
- Device · Drug · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Contrast Enhancement in Magnetic Resonance Imaging
- Interventions
- BAY1747846
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Knoxville, Tennessee
- Conditions
- Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
- Interventions
- Dexamethasone, Normal saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Advanced Malignancies
- Interventions
- CDX-1401 in combination with Resiquimod and/or Poly-ICLC, CDX-1401, Resiquimod, poly-ICLC
- Biological
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Miami Beach, Florida • Detroit, Michigan + 3 more
- Conditions
- Pain, Aging
- Interventions
- RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
- Device
- Lead sponsor
- Teoxane SA
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • New York, New York